News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
The company will provide the technical and financial resources to support the study
The consideration for the acquisition is US $ 2.25 million
_256_384.png)
Cryoballoon catheter ablation, a minimally invasive procedure, is one of the therapeutic modalities to manage Atrial fibrillation
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Subscribe To Our Newsletter & Stay Updated
